Gemalto joins SAFE-BioPharma Association
23 April 2009
Gemalto, a supplier of digital security systems, has become a vendor
partner of SAFE-BioPharma Association.
Gemalto is joining with biopharmaceutical and healthcare industry
leaders to help the industry achieve its common goal of a fully
electronic business environment by 2012. Gemalto will contribute its
expertise in smart card-based solutions for authentication, network
security and digital signature.
Gemalto is the first smart card provider to join SAFE-BioPharma.
Gemalto has been an active industry partner since 2004, when it began
working with Pfizer to implement smart card employee badges that
converge physical and logical access control onto a single identity
credential. Gemalto is also a leading supplier of smart card based
solutions for healthcare identity management worldwide.
The SAFE-BioPharma Association, based in Fort Lee, New Jersey, is a
non-profit association that created and manages the SAFE-BioPharma
digital identity and signature standard for the pharmaceutical and
healthcare industries. The standard provides users with a secure,
enforceable, and regulatory compliant way to verify identities of
parties involved in electronic transactions and to apply their digital
signatures to electronic documents.
“We welcome Gemalto to the growing SAFE-BioPharma vendor partner
community. The company's broad experience in smart cards, digital
security, digital signature and identity management for healthcare,
makes it a valuable global resource for life science companies,” said
Mollie Shields-Uehling, president and chief executive officer, SAFE-BioPharma
“Gemalto is a natural partner to companies using the SAFE-BioPharma
standard, because we provide smart cards and tokens that serve as the
secure carriers for digital identities. Two factor authentication
(something you have and something you know) is an important building
block for the success of many of the proposed Health IT initiatives
underway in the US. For citizens to benefit from the new technologies,
they need to be assured their privacy is protected,” said François
Lasnier, vice president and general manager, Security, for Gemalto North
SAFE-BioPharma Association (www.safe-biopharma.org)
SAFE-BioPharma Association is the non-profit association that created
and manages the SAFE-BioPharma digital identity and signature standard
for the pharmaceutical and healthcare industries.
The SAFE-BioPharma industry standard is used to mitigate legal,
regulatory and other business risk associated with business-to-business
and business-to-regulator electronic transactions.
It facilitates interoperability by providing a secure, enforceable,
and regulatory-compliant way to verify identities of parties involved in
electronic transactions. SAFE-BioPharma’s vision is to be a catalyst in
transforming the biopharmaceutical and healthcare communities to a fully
electronic business environment by 2012.
The Association’s members include:
- Abbott (NYSE: ABT)
- Amgen (NASDAQ: AMGN)
- AstraZeneca (NYSE: AZN)
- Bristol-Myers Squibb (NYSE:BMY)
- GlaxoSmithKline (NYSE: GSK)
- Johnson & Johnson (NYSE: JNJ)
- Eli Lilly (NYSE: LLY)
- Merck (NYSE:MRK)
- National Notary Association
- Organon (NYSE: SGP)
- Pfizer (NYSE: PFE)
- Premier Inc.
- Procter & Gamble (NYSE: PG)
- Sanofi-Aventis (NYSE:SNY).
Bookmark this paget>